Back to Atlas
CTransientStandard research/education caution
CMP-0386
Approved drug
Memantine
Cognition / Neuroprotection
May support cognition/behavior in Alzheimer's disease and glutamatergic excitotoxicity contexts
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Small molecule drug
- Primary mechanism
- Low-affinity uncompetitive NMDA receptor antagonism
- Primary market use
- Alzheimer's disease / neuroprotection
Pharmacology
- Molecular weight (Da)
- 179.26 free base; 215.76 HCl
- Oral bioavailability
- High; well absorbed orally
- Half-life
- ~60-80 h
- Route tags
- Route-dependent / verify
- Evidence level
- Approved
- Clinical status
- Approved drug
- Value-for-money score
- 6 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Not a general smart drug; long half-life and generic cost improve value in indicated contexts